While main results from a platform study of four experimental drugs for amyotrophic lateral sclerosis are negative, it shows ...
GlobalData on MSN6d
Four regimens fail endpoints simultaneously in HEALEY ALS trialALS candidates from Biohaven, Prilenia, Clene and UCB have all failed to halt disease progression versus placebo in the ...
NEW research has shown that pridopidine, a sigma-1 receptor agonist, does not exhibit a significant impact on the progression of amyotrophic lateral sclerosis (ALS) over a 24-week period.
Massachusetts General Hospital coordinated the first four platform trials within the HEALEY ALS platform to evaluate ...
Four more experimental drugs for amyotrophic lateral sclerosis (ALS) have failed to hit the primary endpoint in the phase 2/3 HEALEY ALS basket trial, which is trying to accelerate the search for ...
A new study published in the recent issue of Journal of American Medical Association found that the usage of verdiperstat, a ...
Of the first four experimental ALS treatments tested in the HEALEY platform trial, CNM-Au8 and pridopridine showed some ...
Denali Therapeutics' experimental drug for amyotrophic lateral sclerosis (ALS) failed to show efficacy in part of the phase 2/3 HEALEY ALS basket trial, causing a fall in its share price.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback